Abstract
Ribavirin, an antiviral drug discovered in 1972, is interesting and important for three reasons: (a) it exhibits antiviral activity against a broad range of RNA viruses; (b) it is currently used clinically to treat hepatitis C virus infections, respiratory syncytial virus infections, and Lassa fever virus infections; and (c) ribavirin's mechanism of action has remained unclear for many years. Here we recount the history of ribavirin and review recent reports regarding ribavirin's mechanism of action, including our studies demonstrating that ribavirin is an RNA virus mutagen and ribavirin's primary antiviral mechanism of action against a model RNA virus is via lethal mutagenesis of the RNA virus genomes. Implications for the development of improved versions of ribavirin and for the development of novel antiviral drugs are discussed.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 86-95 |
| Number of pages | 10 |
| Journal | Journal of Molecular Medicine |
| Volume | 80 |
| Issue number | 2 |
| DOIs | |
| State | Published - 2002 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
All Science Journal Classification (ASJC) codes
- Molecular Medicine
- Drug Discovery
- Genetics(clinical)
Fingerprint
Dive into the research topics of 'Ribavirin's antiviral mechanism of action: Lethal mutagenesis?'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver